Gebelikte Bireysel Kullanılan Seçici Serotonin Gerialım İnhibitörleri Yenidoğan ve Çocukluktaki Riskler Açısından Farklılık Gösteriyor Mu: Genel Bakış

Öz

Bu derleme, hamilelik sırasında seçici serotonin geri alım inhibitörlerinin (SSRI’lar) annede bireysel kullanımıyla ilişkili yenidoğan ve çocukluktaki sonuçların risklerine ilişkin mevcut verileri özetlemektedir. Ocak 2005 ile Nisan 2020 arasında İngilizce ve PubMed'de yayınlanan araştırma makaleleri ve meta-analizler tarandı. Sınırlı mevcut verilere göre, diğerlerine kıyasla, bireysel SSRI’larla ilişkili biraz daha yüksek riskler şu şekildedir: erken doğum için paroksetin, düşük doğum ağırlığı için essitalopram, spontan düşük için sertralin ve paroksetin, kalıcı pulmoner hipertansiyon için fluoksetin ve zayıf yenidoğan adaptasyon sendromu olanlar için fluoksetin ve paroksetin. Kalıcı pulmoner hipertansiyon için sertralin ve otizm spektrum bozuklukları için sertralin ve paroksetin diğer SSRI’lara kıyasla nispeten daha güvenli olabilir. Mevcut kanıtlar kesin sonuçlar için yetersizdir. Daha fazla çok merkezli karşılaştırmalı çalışmalara acilen ihtiyaç vardır.

Anahtar Kelimeler

• Antidepresanlar
• Gebelik
• Erken Doğum
• Düşük Doğum Ağırlığı
• Spontan Abortus

Do Individual Selective Serotonin Reuptake Inhibitors Used During Pregnancy Show Any Differences in The Risk of Neonatal and Childhood Outcomes: An Overview

Öz

This review summarizes current data on the risk of neonatal and childhood outcomes associated with maternal use of individual selective serotonin reuptake inhibitors (SSRIs) during pregnancy. Research articles and meta-analyses published in English language and curated in PubMed between January 2005 and April 2020 were screened. Based on limited available data, compared to others, slightly higher risks associated with individual SSRIs are as follows: paroxetine for preterm birth, escitalopram for low birth weight, sertraline and paroxetine for spontaneous abortion, fluoxetine for persistent pulmonary hypertension and fluoxetine and paroxetine for poor neonatal adapdation syndrome. Sertraline for persistent pulmonary hypertension and sertraline and paroxetine for autism spectrum disorders may be relatively safer compared to the other SSRIs. The current evidence is inadequate for definitive conclusions. Futher multicenter comparative studies are urgently needed.

Anahtar Kelimeler

• Antidepressants
• Pregnancy
• Preterm Birth
• Low Birth Weight
• Spontaneous Abortion

Kaynakça

1. Aarnoudse-Moens, C. S., Weisglas-Kuperus, N., van Goudoever, J. B., & Oosterlaan, J. (2009). Meta-analysis of neurobehavioral outcomes in very preterm and/or very low birth weight children. Pediatrics, 124(2), 717-728. https://doi.org/10.1542/peds.2008-2816
2. Allotey, J., Zamora, J., Cheong-See, F., Kalidindi, M., Arroyo-Manzano, D., Asztalos, E., van der Post, J., Mol, B. W., Moore, D., Birtles, D., Khan, K. S., & Thangaratinam, S. (2018). Cognitive, motor, behavioural and academic performances of children born preterm: A meta-analysis and systematic review involving 64 061 children. BJOG: An International Journal of Obstetrics and Gynaecology, 125(1), 16-25. https://doi.org/10.1111/1471-0528.14832
3. Andalib, S., Emamhadi, M. R., Yousefzadeh-Chabok, S., Shakouri, S. K., Høilund-Carlsen, P. F., Vafaee, M. S., & Michel, T. M. (2017). Maternal SSRI exposure increases the risk of autistic offspring: A meta-analysis and systematic review. European Psychiatry: The Journal of The Association of European Psychiatrists, 45, 161-166. https://doi.org/10.1016/j.eurpsy.2017.06.001
4. Baxter, A. J., Brugha, T. S., Erskine, H. E., Scheurer, R. W., Vos, T., & Scott, J. G. (2015). The epidemiology and global burden of autism spectrum disorders. Psychological Medicine, 45(3), 601-613. https://doi.org/10.1017/S003329171400172X
5. Bérard, A., Boukhris, T., & Sheehy, O. (2016). Selective serotonin reuptake inhibitors and autism: Additional data on the Quebec Pregnancy/Birth Cohort. American Journal of Obstetrics and Gynecology, 215(6), 803-805. https://doi.org/10.1016/j.ajog.2016.08.021
6. Biederman J. (2005). Attention-deficit/hyperactivity disorder: A selective overview. Biological Psychiatry, 57(11), 1215-1220. https://doi.org/10.1016/j.biopsych.2004.10.020
7. Biffi, A., Cantarutti, A., Rea, F., Locatelli, A., Zanini, R., & Corrao, G. (2020). Use of antidepressants during pregnancy and neonatal outcomes: An umbrella review of meta-analyses of observational studies. Journal of Psychiatric Research, 124, 99-108. https://doi.org/10.1016/j.jpsychires.2020.02.023
8. Brown, H. K., Ray, J. G., Wilton, A. S., Lunsky, Y., Gomes, T., & Vigod, S. N. (2017). Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children. JAMA, 317(15), 1544-1552. https://doi.org/10.1001/jama.2017.3415

9. Chambers, C. D., Hernandez-Diaz, S., Van Marter, L. J., Werler, M. M., Louik, C., Jones, K. L., & Mitchell, A. A. (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. The New England Journal of Medicine, 354(6), 579-587. https://doi.org/10.1056/NEJMoa052744
10. Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996). Birth outcomes in pregnant women taking fluoxetine. The New England Journal of Medicine, 335(14), 1010-1015. https://doi.org/10.1056/NEJM199610033351402
11. Costei, A. M., Kozer, E., Ho, T., Ito, S., & Koren, G. (2002). Perinatal outcome following third trimester exposure to paroxetine. Archives of Pediatrics & Adolescent Medicine, 156(11), 1129-1132. https://doi.org/10.1001/archpedi.156.11.1129
12. Cuomo, A., Maina, G., Neal, S. M., De Montis, G., Rosso, G., Scheggi, S., Beccarini Crescenzi, B., Bolognesi, S., Goracci, A., Coluccia, A., Ferretti, F., & Fagiolini, A. (2018). Using sertraline in postpartum and breastfeeding: Balancing risks and benefits. Expert Opinion on Drug Safety, 17(7), 719-725. https://doi.org/10.1080/14740338.2018.1491546
13. Damkier, P., Christensen, L. S., & Broe, A. (2018). Patterns and predictors for prescription of psychotropics and mood-stabilizing antiepileptics during pregnancy in Denmark 2000-2016. British Journal of Clinical Pharmacology, 84(11), 2651-2662. https://doi.org/10.1111/bcp.13732
14. Diav-Citrin, O., Shechtman, S., Weinbaum, D., Wajnberg, R., Avgil, M., Di Gianantonio, E., Clementi, M., Weber-Schoendorfer, C., Schaefer, C., & Ornoy, A. (2008). Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study. British Journal of Clinical Pharmacology, 66(5), 695-705. https://doi.org/10.1111/j.1365-2125.2008.03261.x
15. Eke, A. C., Saccone, G., & Berghella, V. (2016). Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics and Gynaecology, 123(12), 1900-1907. https://doi.org/10.1111/1471-0528.14144
16. Ellfolk, M., & Malm, H. (2010). Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reproductive Toxicology, 30(2), 249-260. https://doi.org/10.1016/j.reprotox.2010.04.015
17. Figueiredo, A., Gomes-Filho, I. S., Silva, R. B., Pereira, P., Mata, F., Lyrio, A. O., Souza, E. S., Cruz, S. S., & Pereira, M. G. (2018). Maternal Anemia and Low Birth Weight: A Systematic Review and Meta-Analysis. Nutrients, 10(5), 601. https://doi.org/10.3390/nu10050601
18. Forsberg, L., Navér, L., Gustafsson, L. L., & Wide, K. (2014). Neonatal adaptation in infants prenatally exposed to antidepressants--clinical monitoring using Neonatal Abstinence Score. PloS One, 9(11), e111327. https://doi.org/10.1371/journal.pone.0111327
19. Frey, H. A., & Klebanoff, M. A. (2016). The epidemiology, etiology, and costs of preterm birth. Seminars in Fetal & Neonatal Medicine, 21(2), 68-73. https://doi.org/10.1016/j.siny.2015.12.011
20. Goldenberg, R. L., Culhane, J. F., Iams, J. D., & Romero, R. (2008). Epidemiology and causes of preterm birth. Lancet, 371(9606), 75-84. https://doi.org/10.1016/S0140-6736(08)60074-4
21. Grigoriadis, S., Graves, L., Peer, M., Mamisashvili, L., Tomlinson, G., … Richter, M. (2018). Maternal anxiety during pregnancy and the association with adverse perinatal outcomes: Systematic review and meta-analysis. The Journal of Clinical Psychiatry, 79(5), 17r12011. https://doi.org/10.4088/JCP.17r12011
22. Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Eady, A., Tomlinson, G., Dennis, C. L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., & Ross, L. E. (2013a). The effect of prenatal antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 74(4), 309-320. https://doi.org/10.4088/JCP.12r07967
23. Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Roerecke, M., Rehm, J., Dennis, C. L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., & Ross, L. E. (2013c). Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. The Journal of Clinical Psychiatry, 74(4), 293-308. https://doi.org/10.4088/JCP.12r07966
24. Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Tomlinson, G., Dennis, C. L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., Radford, K., Martinovic, J., & Ross, L. E. (2013b). The impact of maternal depression during pregnancy on perinatal outcomes: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 74(4), 321-341. https://doi.org/10.4088/JCP.12r07968
25. Grigoriadis, S., Vonderporten, E. H., Mamisashvili, L., Tomlinson, G., Dennis, C. L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., & Ross, L. E. (2014). Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: Systematic review and meta-analysis. BMJ, 348, f6932. https://doi.org/10.1136/bmj.f6932
26. Grote, N. K., Bridge, J. A., Gavin, A. R., Melville, J. L., Iyengar, S., & Katon, W. J. (2010). A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Archives of General Psychiatry, 67(10), 1012-1024. https://doi.org/10.1001/archgenpsychiatry.2010.111
27. Grzeskowiak, L. E., Gilbert, A. L., & Morrison, J. L. (2012). Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology, 32(5), 615-621. https://doi.org/10.1097/JCP.0b013e31826686bc
28. Halvorsen, A., Hesel, B., Østergaard, S. D., & Danielsen, A. A. (2019). In utero exposure to selective serotonin reuptake inhibitors and development of mental disorders: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica, 139(6), 493-507. https://doi.org/10.1111/acps.13030
29. Hayes, R. M., Wu, P., Shelton, R. C., Cooper, W. O., Dupont, W. D., … Hartert, T. V. (2012). Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. American Journal of Obstetrics and Gynecology, 207(1), 49.e1-49.e499. https://doi.org/10.1016/j.ajog.2012.04.028
30. Hemels, M. E., Einarson, A., Koren, G., Lanctôt, K. L., & Einarson, T. R. (2005). Antidepressant use during pregnancy and the rates of spontaneous abortions: A meta-analysis. The Annals of Pharmacotherapy, 39(5), 803-809. https://doi.org/10.1345/aph.1E547
31. Huang, H., Coleman, S., Bridge, J. A., Yonkers, K., & Katon, W. (2014). A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. General Hospital Psychiatry, 36(1), 13-18. https://doi.org/10.1016/j.genhosppsych.2013.08.002
32. Jiang, H. Y., Peng, C. T., Zhang, X., & Ruan, B. (2018). Antidepressant use during pregnancy and the risk of attention-deficit/hyperactivity disorder in the children: a meta-analysis of cohort studies. BJOG: An International Journal of Obstetrics and Gynaecology, 125(9), 1077-1084. https://doi.org/10.1111/1471-0528.15059
33. Källén, B., & Olausson, P. O. (2008). Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety, 17(8), 801-806. https://doi.org/10.1002/pds.1570
34. Kaplan, Y. C., Keskin-Arslan, E., Acar, S., & Sozmen, K. (2016). Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis. Reproductive Toxicology, 66, 31-43. https://doi.org/10.1016/j.reprotox.2016.09.013
35. Kaplan, Y. C., Keskin-Arslan, E., Acar, S., & Sozmen, K. (2017). Maternal SSRI discontinuation, use, psychiatric disorder and the risk of autism in children: a meta-analysis of cohort studies. British Journal of Clinical Pharmacology, 83(12), 2798-2806. https://doi.org/10.1111/bcp.13382
36. Kieler, H., Artama, M., Engeland, A., Ericsson, O., Furu, K., … Haglund, B. (2012). Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population-based cohort study from the five Nordic countries. BMJ, 344, d8012. https://doi.org/10.1136/bmj.d8012
37. Kieviet, N., Dolman, K. M., & Honig, A. (2013). The use of psychotropic medication during pregnancy: How about the newborn? Neuropsychiatric Disease and Treatment, 9, 1257-1266. https://doi.org/10.2147/NDT.S36394
38. Kjaersgaard, M. I., Parner, E. T., Vestergaard, M., Sørensen, M. J., Olsen, J., … Pedersen, L. H. (2013). Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PloS One, 8(8), e72095. https://doi.org/10.1371/journal.pone.0072095
39. Klieger-Grossmann, C., Weitzner, B., Panchaud, A., Pistelli, A., Einarson, T., … Einarson, A. (2012). Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. Journal of Clinical Pharmacology, 52(5), 766-770. https://doi.org/10.1177/0091270011405524
40. Klinger, G., & Merlob, P. (2008). Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. The Israel Journal of Psychiatry and Related Sciences, 45(2), 107-113.
41. Lattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., Jr, & Vazquez, D. M. (2005). Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. Journal of Perinatology: Official Journal of The California Perinatal Association, 25(9), 595-604. https://doi.org/10.1038/sj.jp.7211352
42. Lord, C., Elsabbagh, M., Baird, G., & Veenstra-Vanderweele, J. (2018). Autism spectrum disorder. Lancet, 392(10146), 508-520. https://doi.org/10.1016/S0140-6736(18)31129-2
43. Man, K. K., Tong, H. H., Wong, L. Y., Chan, E. W., Simonoff, E., & Wong, I. C. (2015). Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies. Neuroscience and Biobehavioral Reviews, 49, 82-89. https://doi.org/10.1016/j.neubiorev.2014.11.020
44. Man, K., Chan, E. W., Ip, P., Coghill, D., Simonoff, E., Chan, P., Lau, W., Schuemie, M. J., Sturkenboom, M., & Wong, I. (2018). Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 86, 1-11. https://doi.org/10.1016/j.neubiorev.2017.12.007
45. Masarwa, R., Bar-Oz, B., Gorelik, E., Reif, S., Perlman, A., & Matok, I. (2019). Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: A systematic review, meta-analysis, and network meta-analysis. American Journal of Obstetrics and Gynecology, 220(1), 57.e1-57.e13. https://doi.org/10.1016/j.ajog.2018.08.030
46. McDonagh, M. S., Matthews, A., Phillipi, C., Romm, J., Peterson, K., Thakurta, S., & Guise, J. M. (2014). Depression drug treatment outcomes in pregnancy and the postpartum period: a systematic review and meta-analysis. Obstetrics and Gynecology, 124(3), 526-534. https://doi.org/10.1097/AOG.0000000000000410
47. Meunier, M. R., Bennett, I. M., & Coco, A. S. (2013). Use of antidepressant medication in the United States during pregnancy, 2002-2010. Psychiatric Services, 64(11), 1157-1160. https://doi.org/10.1176/appi.ps.201200455
48. Modabbernia, A., Velthorst, E., & Reichenberg, A. (2017). Environmental risk factors for autism: An evidence-based review of systematic reviews and meta-analyses. Molecular Autism, 8, 13. https://doi.org/10.1186/s13229-017-0121-4
49. Molenaar, N. M., Bais, B., Lambregtse-van den Berg, M. P., Mulder, C. L., Howell, E. A., Fox, N. S., Rommel, A. S., Bergink, V., & Kamperman, A. M. (2020). The international prevalence of antidepressant use before, during, and after pregnancy: A systematic review and meta-analysis of timing, type of prescriptions and geographical variability. Journal of Affective Disorders, 264, 82-89. https://doi.org/10.1016/j.jad.2019.12.014
50. Munk-Olsen, T., Gasse, C., & Laursen, T. M. (2012). Prevalence of antidepressant use and contacts with psychiatrists and psychologists in pregnant and postpartum women. Acta Psychiatrica Scandinavica, 125(4), 318-324. https://doi.org/10.1111/j.1600-0447.2011.01784.x
51. Nakhai-Pour, H. R., Broy, P., & Bérard, A. (2010). Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ: Canadian Medical Association Journal, 182(10), 1031-1037. https://doi.org/10.1503/cmaj.091208
52. Ng, Q. X., Venkatanarayanan, N., Ho, C., Sim, W. S., Lim, D. Y., & Yeo, W. S. (2019). Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn: An Update Meta-Analysis. Journal of Women’s Health, 28(3), 331-338. https://doi.org/10.1089/jwh.2018.7319
53. Occhiogrosso, M., Omran, S. S., & Altemus, M. (2012). Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. The American Journal of Psychiatry, 169(2), 134-140. https://doi.org/10.1176/appi.ajp.2011.11040553
54. Roca, A., Garcia-Esteve, L., Imaz, M. L., Torres, A., Hernández, S., … Martin-Santos, R. (2011). Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: The relevance of dose. Journal of Affective Disorders, 135(1-3), 208-215. https://doi.org/10.1016/j.jad.2011.07.022
55. Sanz, E. J., De-las-Cuevas, C., Kiuru, A., Bate, A., & Edwards, R. (2005). Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet, 365(9458), 482-487. https://doi.org/10.1016/S0140-6736(05)17865-9
56. Sciberras, E., Mulraney, M., Silva, D., & Coghill, D. (2017). Prenatal risk factors and the etiology of ADHD-review of existing evidence. Current Psychiatry Reports, 19(1), 1. https://doi.org/10.1007/s11920-017-0753-2
57. Sharifi, N., Khazaeian, S., Pakzad, R., Fathnezhad Kazemi, A., & Chehreh, H. (2017). Investigating the Prevalence of Preterm Birth in Iranian Population: A Systematic Review and Meta-Analysis. Journal of Caring Sciences, 6(4), 371-380. https://doi.org/10.15171/jcs.2017.035
58. Sharma, V., Berkelhamer, S., & Lakshminrusimha, S. (2015). Persistent pulmonary hypertension of the newborn. Maternal Health, Neonatology and Perinatology, 1, 14. https://doi.org/10.1186/s40748-015-0015-4
59. Simon, G. E., Cunningham, M. L., & Davis, R. L. (2002). Outcomes of prenatal antidepressant exposure. The American Journal of Psychiatry, 159(12), 2055-2061. https://doi.org/10.1176/appi.ajp.159.12.2055
60. Sivojelezova, A., Shuhaiber, S., Sarkissian, L., Einarson, A., & Koren, G. (2005). Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome. American Journal of Obstetrics and Gynecology, 193(6), 2004-2009. https://doi.org/10.1016/j.ajog.2005.05.012
61. Suri, R., Altshuler, L., Hellemann, G., Burt, V. K., Aquino, A., & Mintz, J. (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. The American Journal of Psychiatry, 164(8), 1206-1213. https://doi.org/10.1176/appi.ajp.2007.06071172
62. Thomas, R., Sanders, S., Doust, J., Beller, E., & Glasziou, P. (2015). Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics, 135(4), 994-1001. https://doi.org/10.1542/peds.2014-3482
63. Tucker, J., & McGuire, W. (2004). Epidemiology of preterm birth. BMJ, 329(7467), 675-678. https://doi.org/10.1136/bmj.329.7467.675
64. Uguz F. (2016). A pharmacological approach to panic disorder during pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine: The Official Journal of The European Association of Perinatal Medicine, The Federation of Asia And Oceania Perinatal Societies, The International Society of Perinatal Obstetricians, 29(9), 1468-1475. https://doi.org/10.3109/14767058.2015.1051025
65. Uguz F. (2018). Maternal antidepressant use during pregnancy and the risk of attention-deficit/hyperactivity disorder in children: A systematic review of the current literature. Journal of Clinical Psychopharmacology, 38(3), 254-259. https://doi.org/10.1097/JCP.0000000000000868
66. Viktorin, A., Uher, R., Reichenberg, A., Levine, S. Z., & Sandin, S. (2017). Autism risk following antidepressant medication during pregnancy. Psychological Medicine, 47(16), 2787-2796. https://doi.org/10.1017/S0033291717001301
67. Wen, S. W., Smith, G., Yang, Q., & Walker, M. (2004). Epidemiology of preterm birth and neonatal outcome. Seminars in Fetal & Neonatal Medicine, 9(6), 429-435. https://doi.org/10.1016/j.siny.2004.04.002
68. Xu, J., Barinas-Mitchell, E., Kuller, L. H., Youk, A. O., & Catov, J. M. (2014). Maternal hypertension after a low-birth-weight delivery differs by race/ethnicity: Evidence from the National Health and Nutrition Examination Survey (NHANES) 1999-2006. PloS One, 9(8), e104149. https://doi.org/10.1371/journal.pone.0104149
69. Yadav, H., & Lee, N. (2013). Maternal factors in predicting low birth weight babies. The Medical Journal of Malaysia, 68(1), 44-47.
70. Yonkers, K. A., Blackwell, K. A., Glover, J., & Forray, A. (2014). Antidepressant use in pregnant and postpartum women. Annual Review of Clinical Psychology, 10, 369-392. https://doi.org/10.1146/annurev-clinpsy-032813-153626